Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research

Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1

Joanne M. LangleyComments to Author , Soren Gantt, Caroline Quach, Julie A. Bettinger, Scott A. Halperin, Jill Mutch, Shelly A. McNeil, Brian J. Ward, Donna MacKinnon-Cameron, Lingyun Ye, Kim Marty, David Scheifele, Erin Brown, Joenel Alcantara, and The Canadian Immunization Research Network
Author affiliations: Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada (J.M. Langley, S.A. Halperin, J. Mutch, S.A. McNeil, D. MacKinnon-Cameron, L. Ye); Vaccine Evaluation Center, University of British Columbia, Vancouver, British Columbia, Canada (S. Gantt, J.A. Bettinger, K. Marty, D. Scheifele); University of Montreal, Montreal, Quebec, Canada (C. Quach); Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada (C. Quach, B.J. Ward); University of Calgary, Calgary, Alberta, Canada (E. Brown, J. Alcantara)

Main Article

Figure 3

GMTs of hSBA titers to 3 vaccine strains in recipients in trial of 4-component protein-based meningococcal B vaccine administered at 0 and 21 days compared with 0 and 60 days, Canada. A) hSBA 5/99; B) hSBA H44/76; C) hSBA 982/54. Error bars indicate 95% CIs. GMT, geometric mean titer; hSBA, human serum bactericidal antibody; hSBA 5/99, Neisserial adhesin A surface proteins; hSBA H44/76, factor H binding protein; hSBA 982/54, New Zealand outer membrane vesicle.

Figure 3. GMTs of hSBA titers to 3 vaccine strains in recipients in trial of 4-component protein-based meningococcal B vaccine administered at 0 and 21 days compared with 0 and 60 days, Canada. A) hSBA 5/99; B) hSBA H44/76; C) hSBA 982/54. Error bars indicate 95% CIs. GMT, geometric mean titer; hSBA, human serum bactericidal antibody; hSBA 5/99, Neisserial adhesin A surface proteins; hSBA H44/76, factor H binding protein; hSBA 982/54, New Zealand outer membrane vesicle.

Main Article

1Preliminary results from this study were presented at IDWeek, October 26–30, 2016, New Orleans, LA, USA; and at the Meningitis Research Foundation Conference, November 14–15, 2017, London, England, UK.

Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external